STOCK TITAN
  1. Home
  2. News
  3. VTYX

Ventyx Biosciences Inc - VTYX STOCK NEWS

Welcome to our dedicated news page for Ventyx Biosciences (Ticker: VTYX), a resource for investors and traders seeking the latest updates and insights on Ventyx Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ventyx Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ventyx Biosciences's position in the market.

News
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
Rhea-AI Summary
Ventyx Biosciences, Inc. (VTYX) provides updates on its NLRP3 inhibitor portfolio, showcasing positive Phase 1 and Phase 2 trial results. The company plans to advance its CNS-penetrant NLRP3 inhibitor, VTX3232, into Phase 2a trials for Parkinson's disease and obesity. Additionally, VTX2735 demonstrates clinical proof of concept in CAPS patients, paving the way for evaluation in cardiovascular diseases. Ventyx's cash position is strengthened by recent PIPE financing, ensuring funding for operations until at least H2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.95%
Tags
clinical trial
-
News
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
Rhea-AI Summary
Ventyx Biosciences, Inc. (VTYX) announced a private placement of 11,174,000 shares of common stock at $8.95 per share, expecting gross proceeds of around $100 million. The private placement, led by Farallon Capital Management, aims to fund the clinical and preclinical development of various programs, extending cash runway into at least the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.18%
Tags
none
-
News
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Ventyx Biosciences, Inc. (VTYX) announced its participation in upcoming investor conferences, including Jefferies Biotech on the Bay Summit and Barclays 26th Annual Global Healthcare Conference. The company focuses on developing novel oral therapies for inflammatory diseases with unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
conferences
News
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
Rhea-AI Summary
Ventyx Biosciences, Inc. (VTYX) will host a virtual investor event to provide key clinical updates on their NLRP3 inhibitor portfolio, including Phase 2 trial results for VTX2735 in CAPS and Phase 1 trial results for VTX3232 in healthy volunteers. They will also discuss updates from the ongoing open-label extension of the VTX002 Phase 2 trial in ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
conferences
-
News
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
Rhea-AI Summary
Ventyx Biosciences, Inc. (VTYX) announced financial results for Q4 and full year 2023, with $252.2 million in cash reserves. They plan to provide clinical updates on their NLRP3 portfolio at a virtual investor event on March 11th, including results from various trials. The company is focused on developing novel oral therapies for inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.43%
Tags
earnings
-
News
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
Rhea-AI Summary
Ventyx Biosciences, Inc. (VTYX) to present Phase 2 trial results of VTX002 in ulcerative colitis at ECCO Congress. The data highlight the efficacy and safety of VTX002 as a potential oral therapy for UC, showcasing promising outcomes in endoscopic remission and mucosal improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.48%
Tags
conferences clinical trial
News
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Ventyx Biosciences, Inc. (Nasdaq: VTYX) announces participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The clinical-stage biopharmaceutical company focuses on advancing novel oral therapies for inflammatory diseases with significant unmet medical need. The event will be held virtually on February 13, 2024, with a webcast available on the Ventyx website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
conferences
-
News
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
Ventyx Biosciences, Inc. (VTYX) executives will participate in the 35th Annual Piper Sandler Healthcare Conference on November 28, 2023, in New York, NY. The company is a clinical-stage biopharmaceutical firm focusing on advancing novel oral therapies for various inflammatory diseases with significant unmet medical needs. A webcast of the presentation will be available on the Ventyx website, with a replay available for thirty days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences
-
News
Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference
Rhea-AI Summary
Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced its participation in the Jefferies London Healthcare Conference, presenting on November 16, 2023, to discuss its novel oral therapies for inflammatory diseases. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.17%
Tags
conferences
News
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
Rhea-AI Summary
Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced financial results for Q3 2023, with $300.8 million in cash, and provided updates on their clinical-stage portfolio. The updates include Phase 2 data for VTX002 in ulcerative colitis, an interim efficacy analysis for VTX958 in Crohn’s disease, and updates on Phase 2 trials for VTX2735 and VTX3232. Financially, R&D expenses were $49.8 million, G&A expenses were $8.2 million, and net loss was $54.0 million for the quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.17%
Tags
earnings
Stock VTYX logo
Ventyx Biosciences Inc

Nasdaq:VTYX

VTYX Rankings

#3493 Ranked by Market Cap
#4794 Ranked by Stock Gains
N/A Ranked by Dividends

VTYX Stock Data

324.30M
40.61M
3.2%
89.51%
13.09%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Encinitas

About VTYX

we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.